AR和EGR1与三阴性乳腺癌临床病理特征、预后的关系

doi:10.3760/cma.j.cn441417-20240814-14017

摘要/Abstract

摘要：

目的　分析雄激素受体（androgen receptor，AR）、早期生长反应基因1（early growth response gene-1，EGR1）在三阴性乳腺癌中的表达情况，探讨二者与三阴性乳腺癌临床特征和预后的关系。方法　选取陕西省肿瘤医院2022年3月至2024年3月收治的100例三阴性乳腺癌患者为研究组，年龄（48.21±7.52）岁，病程（16.12±3.21）个月；选取同期100例非三阴性乳腺癌患者为参照组，年龄（47.54±5.68）岁，病程（16.32±3.24）个月。采用免疫组织化学法检测AR和EGR1表达情况，对比参照组、癌组织和癌旁组织AR、EGR1阳性表达率。分析癌组织中AR、EGR1表达与病理特征的相关性。将三阴性乳腺癌患者根据预后分成存活组和死亡组，对比两组AR和EGR1表达情况。统计学方法采用独立样本t检验、χ²检验和多元线性回归分析。结果　癌组织AR阳性表达率为22.00%（22/100），EGR1高表达率为21.00%（21/100），低于参照组的52.00%（52/100）与45.00%（45/100）和癌旁组织的78.00%（78/100）与78.00%（78/100），差异均有统计学意义（χ²=62.838、52.415，均P<0.05）。浸润性导管癌、Ⅰ～Ⅱ级患者、Ki-67指数<14%的三阴性乳腺癌患者AR阳性表达率分别为29.17%（21/72）、27.94%（19/68）和45.95%（17/37），组间对比，差异均有统计学意（χ²=7.696、4.371、19.625，均P<0.05）。肿瘤长径<3 cm、Ⅰ～Ⅱ级患者、Ⅰ～Ⅱ期患者、无淋巴结转移、Ki-67指数<14%的三阴性乳腺癌患者EGR1高表达率分别为42.22%（19/45）、27.94%（19/68）、27.69%（18/65）、40.74%（11/27）、48.65%（18/37），组间对比，差异均有统计学意义（χ²=22.212、6.171、5.014、6.573、27.062，均P<0.05）。存活组AR阳性表达率为43.18%（19/44），EGR1高表达率为45.45%（20/44），均高于死亡组（χ²=20.543、28.323，均P<0.05）。结论　三阴性乳腺癌患者AR、ERG-1异常表达，与疾病病理分期和Ki-67等病理特征密切相关，且对患者预后有显著影响。

关键词: 三阴性乳腺癌, 雄激素受体, 早期生长反应基因, 临床特征, 预后, 相关性

Abstract:

Objective　To analyze the expressions of androgen receptor (AR) and early growth response gene-1 (EGR1) in triple-negative breast cancer, and to explore their relationship with the clinical features and prognosis. Methods　One hundred patients with triple-negative breast cancer treated at Shaanxi Provincial Cancer Hospital from March 2022 to March 2024 were selected as a study group; they were (48.21±7.52) years old; their disease course was (16.12±3.21) months. One hundred patients with non-triple-negative breast cancer during the same period were selected as a reference group; they were (47.54±5.68) years old; their disease course was (16.32±3.24) months. Immunohistochemistry was used to detect the AR and EGR1 expressions. The positive expression rates of AR and EGR1 in the reference group, carcinoma tissue, and adjacent tissue were compared. The correlation of AR and EGR1 expressions in the cancer tissue with the pathological characteristics was also analyzed. The patients with triple-negative breast cancer were divided into a survival group and a death group according to their prognosis, and the AR and EGR1 expressions were compared between the two groups. The statistical methods included the independent sample t test, χ² test, and multiple linear regression analysis. Results　The positive expression rate of AR and the high expression rate of EGR1 in the cancer tissue were 22.00% (22/100) and 21.00% (21/100), which were lower than those in the reference group [52.00% (52/100) and 45.00% (45/100)] and those in the adjacent tissue [78.00% (78/100) and 78.00% (78/100)], with statistical differences (χ²=62.838 and 52.415; both P<0.05). The AR positive expression rates of the triple-negative breast cancer patients with invasive ductal carcinoma, grade Ⅰ-Ⅱ, and Ki-67 index <14% were 29.17% (21/72), 27.94% (19/68), and 45.95% (17/37), respectively; there were statistical differences between the groups (χ²=7.696, 4.371, and 19.625; all P<0.05). The high expression rates of EGR1 in the patients with tumor diameter <3 cm, grade Ⅰ-Ⅱ, stage Ⅰ-Ⅱ, no lymph node metastasis, and Ki-67 index <14% were 42.22% (19/45), 27.94% (19/68), 27.69% (18/65), 40.74% (11/27), and 48.65% (18/37), respectively; there were statistical differences between the groups (χ²=22.212, 6.171, 5.014, 6.573, and 27.062; all P<0.05). The positive expression rate of AR and the high expression rate of EGR1 in the survival group were 43.18% (19/44) and 45.45% (20/44), which were higher than those in the death group (χ²=20.543 and 28.323; both P<0.05). Conclusion　The abnormal expressions of AR and ERG1 in patients with triple-negative breast cancer are closely related to the pathological stage and pathological features such as Ki-67, and have significant impact on their prognosis.

Key words: Triple-negative breast cancer, , Androgen receptor, , Early growth response genes, , Clinical features, , Prognosis, , Correlation

黄颖楠丁彩霞康博.

AR和EGR1与三阴性乳腺癌临床病理特征、预后的关系 [J]. 国际医药卫生导报, 2025, 31(14): 2373-2377.

Huang Yingnan, Ding Caixia, Kang Bo.

Relationship of AR and EGR1 with clinicopathological features and prognosis of patients with triple-negative breast cancer [J]. International Medicine and Health Guidance News, 2025, 31(14): 2373-2377.

参考文献

[1]石蕾,罗吉红.三阴性乳腺癌组织中Del-1与TWEAK蛋白表达及其临床意义[J].药物生物技术, 2020, 27(2): 140-144. DOI: 10.19526/j.cnki.1005-8915.20200210.

[2]Gourgue F, Mignion L, Van Hul M, et al. Obesity and triple-negative-breast-cancer: is apelin a new key target[J]. J Cell Mol Med, 2020, 24(17): 10233-10244. DOI: 10.1111/jcmm.15639.Epub 2020 Jul 17.

[3]马珊珊,范静婧,王一,等.三阴性乳腺癌预后因素分析及预测模型构建[J].中华肿瘤防治杂志, 2022, 29(15): 1099-1105. DOI: 10.16073/j.cnki.cjcpt.2022.15.03.

[4]王子溪,孙红梅,陈心仪,等. 52例三阴性乳腺癌的临床特征与预后分析[J].西部医学, 2023, 35(7): 1015-1018. DOI: 10.3969/j.issn.1672-3511.2023.07.015.

[5]李岩,王兴河.基于生物信息学分析三阴性乳腺癌的差异表达基因和药物靶点挖掘[J].中国临床药理学杂志, 2024, 40(2): 269-272. DOI: 10.13699/j.cnki.1001-6821. 2024.02.024.

[6]郑威,商海涛,庞欣欣,等.基于网络药理学和分子对接研究昆明山海棠治疗糖尿病肾病的作用机制[J].药物生物技术, 2023, 30(1): 12-18. DOI: 10.19526/j.cnki.1005-8915.20230103.

[7]蒋艳,李莉,李安然.三阴性乳腺癌组织中雄激素受体、肿瘤抑制蛋白P53的表达及与预后的关系[J].实用癌症杂志, 2023, 38(3): 379-382. DOI: 10.3969/j.issn.1001-5930. 2023.03.007.

[8]艾勇彪,黄军,袁杰,等.早期三阴性乳腺癌中雄激素受体表达与临床病理特征及预后的关系[J].实用医学杂志, 2023, 39(8): 975-979. DOI: 10.3969/j.issn.1006-5725.2 023.08.010.

[9]Lan Y, Han X, Huang F, et al. Early growth response gene-1 deficiency interrupts TGFβ1 signaling activation and aggravates neurodegeneration in experimental autoimmune encephalomyelitis mice[J]. Neurosci Bull, 2024, 40(3): 283-292. DOI: 10.1007/s12264-023- 01111-z.

[10]李康乐,杨小蒨,张愉,等.阳和汤对三阴性乳腺癌细胞MDA-MB-231凋亡Egr1/p21信号通路的影响[J].中国实验方剂学杂志, 2020, 26(8): 62-67. DOI: 10.13422/j.cnki.syfjx.20200424.

[11]Jatoi Ismail, Rody Achim.乳腺疾病诊疗学[M].2版.北京:中国科学技术出版社, 2020: 11-13.

[12]陶豫洁,张琳,陈东辉. AR在ER阳性和阴性乳腺癌中的表达及其临床意义[J].实用癌症杂志, 2023, 38(6): 879-881. DOI: 10.3969/j.issn.1001-5930.2023.06.003.

[13]罗晓蓉,罗川勤. TVCDS在评估宫颈癌发展程度及疾病分期中的价值及其与Egr-1表达的关系研究[J].现代医学, 2020, 48(1): 92-96. DOI: 10.3969/j.issn.1671-7562. 2020.01.020.

[14]Ghannam SF, Rutland CS, Allegrucci C, et al. Defining invasion in breast cancer: the role of basement membrane[J]. J Clin Pathol, 2023, 76(1): 11-18. DOI: 10.1136/jcp-2022-208584.

[15]刘家伟.三阴性乳腺癌患者腋窝淋巴结转移的危险因素分析及其预测模型的建立[J].江苏医药, 2024, 50(3): 276-280. DOI: 10.19460/j.cnki.0253-3685.2024.03.014.

[16]景娜,马琴,蒋倩,郑苗丽.≥60岁三阴性乳腺癌临床病理特征与预后分析[J].中国药物与临床, 2020, 20(16): 2720-2722. DOI: 10.11655/zgywylc2020.16.025.

[17]李浩,廖小丽,喻朝霞.乳腺原发性鳞状细胞癌与三阴性乳腺癌临床特征、治疗及预后的比较[J].东南大学学报(医学版), 2020, 39(6): 787-792. DOI: 10.3969/j.issn.1671-6264.2020.06.015.

[18]Walsh EM, Gucalp A, Patil S, et al. Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer:a feasibility study[J]. Breast Cancer Res Treat, 2022, 195(3): 341-351. DOI: 10.1007/s10549-022-06669-2.

[19]任晓燕,陶玉梅,金晓霞,等.雄激素受体在不同分子分型乳腺癌中的表达及临床病理意义[J].南京医科大学学报(自然科学版), 2020, 40(1): 62-66. DOI: 10.7655/NYDXBNS20200112.

[20]张科,刘志良,陈雪,等. BRCA1、AR及Ki-67在三阴性乳腺癌中的表达及临床病理意义[J].实用癌症杂志, 2021, 36(9): 1398-1401. DOI: 10.3969/j.issn.1001-5930. 2021.09.002.

[21]丛玲华,方来福,顾昕,等.早期生长反应基因在宫颈癌中的表达及与高危型人乳头瘤病毒感染的关系[J].中国妇幼保健, 2021, 36(2): 401-404. DOI: 10.19829/j.zgfybj.issn.1001-4411.2021.02.049.

[22]郭瑞霞,陈玲燕,张岩. EGR1在乳腺癌组织中的表达及临床意义[J].现代肿瘤医学, 2022, 30(10): 1767-1771. DOI: 10.3969/j.issn.1672-4992.2022.10.010.

[23]Fan H, Wang Y, Tang X, et al. Expression of early growth responsive gene-1 in the visual cortex of monocular form deprivation amblyopic kittens[J]. BMC Ophthalmol, 2021, 21(1): 394. DOI: 10.1186/s12886-021-02161-5.

[24]李娇,刘海. USP7调节EGR1的表达对喉癌细胞生物学行为的影响[J].中国耳鼻咽喉颅底外科杂志, 2021, 27(5): 523-529. DOI: 10.11798/j.issn.1007-1520.202150005.

[25]周钧,汪庭军,唐珍.甲状腺乳头状癌患者血清EGR1/2 mRNA水平检测在临床早期实验诊断中的价值研究[J].现代检验医学杂志, 2023, 38(5): 93-98. DOI: 10.3969/j.issn.1671-7414.2023.05.018.

[26]唐良成,吕栋,徐芳.三阴性乳腺癌组织中EGR1表达与临床病理特征预后的相关性[J].河北医学, 2023, 29(3): 431-436. DOI: 10.3969/j.issn.1006-6233.2023.03.016.

[27]刘延梅,马少君,马庆,等.雄激素受体在三阴性乳腺癌组织中的表达及其与临床病理特征及预后的相关性[J].现代肿瘤医学, 2021, 29(13): 2269-2273. DOI: 10.3969/j.issn.1672-4992.2021.13.014.

[28]罗含欢,姜英,边巴扎西,等.西藏地区非特殊型浸润性乳腺癌雄激素受体的表达及其与不同分子分型及临床病理特征的相关性[J].中国医学科学院学报, 2022, 44(6): 1033-1039. DOI: 10.3881/j.issn.1000-503X.14724.

[29]张换,毛大华.雄激素受体信号通路与乳腺癌关系的研究进展[J].医学综述, 2021, 27(16): 3188-3192. DOI: 10.3969/j.issn.1006-2084.2021.16.013.

[30]徐英杰,李巍.三阴性乳腺癌早期患者雄激素受体、Ki67、p53、表皮生长因子受体表达水平及其与临床病理特征关系研究[J].陕西医学杂志, 2021, 50(12): 1594-1597. DOI: 10.3969/j.issn.1000-7377.2021.12.032.